Bristol-Myers Squibb
BMY
2,267 hedge funds and large institutions have $71.6B invested in Bristol-Myers Squibb in 2025 Q3 according to their latest regulatory filings, with 160 funds opening new positions, 832 increasing their positions, 986 reducing their positions, and 150 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 16 → 20 (+4)
7% more first-time investments, than exits
New positions opened: 160 | Existing positions closed: 150
3% less call options, than puts
Call options by funds: $1.39B | Put options by funds: $1.44B
1% less funds holding
Funds holding: 2,292 → 2,267 (-25)
2.8% less ownership
Funds ownership: 80.8% → 78% (-2.8%)
6% less capital invested
Capital invested by funds: $76.5B → $71.6B (-$4.91B)
16% less repeat investments, than reductions
Existing positions increased: 832 | Existing positions reduced: 986
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VanEck Associates
New York
|
+$277M |
| 2 |
Goldman Sachs
New York
|
+$246M |
| 3 |
Two Sigma Investments
New York
|
+$214M |
| 4 |
Two Sigma Advisers
New York
|
+$168M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$165M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$1.58B |
| 2 |
JP Morgan Chase
New York
|
-$830M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$405M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$277M |
| 5 |
Bank of New York Mellon
New York
|
-$196M |
BMY Hedge Fund Activity: Q3 2025 in Review
2,267 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q3 2025, worth a combined $71.6B — down 6.4% from $76.5B a quarter earlier.
Buyers outnumbered sellers: 160 funds opened new BMY positions and 150 closed out — a net gain of 10 holders — while 832 added to existing stakes and 986 trimmed.
The largest buyer was VanEck Associates, adding an estimated $277M. The largest seller was Capital International Investors, cutting an estimated $1.58B.
- 2,267 institutional investors held Bristol-Myers Squibb (BMY) as of Q3 2025, down from 2,292 in Q2 2025.
- Funds reported $71.6B of Bristol-Myers Squibb stock for Q3 2025, down 6.4% quarter-over-quarter.
- 160 funds opened new Bristol-Myers Squibb positions in Q3 2025 and 150 closed out, a net change of +10 holders.
- The largest Bristol-Myers Squibb buyer in Q3 2025 was VanEck Associates, an estimated $277M added.
- The largest Bristol-Myers Squibb seller in Q3 2025 was Capital International Investors, an estimated $1.58B sold.
Based on aggregated 13F filings for Q3 2025.